摘要
目的:观察纳洛酮对肺性脑病患者治疗的效果及安全性。方法:肺性脑病患者50例随机分为观察组和对照组。所有患者均通过无创呼吸机进行持续吸氧,对照组患者给予常规治疗,观察组患者在对照组治疗基础上加用纳洛酮治疗,7 d为1个疗程。观察两组患者的临床疗效、相关临床指标及药品不良反应发生情况。结果:观察组总有效率为92.00%,高于对照组的72.00%,但差异无统计学意义(P>0.05)。两组患者治疗后的pH水平、PaO_2及PaCO_2水平、血管紧张素Ⅱ及白细胞介素-8(IL-8)水平均较治疗前明显改善(P<0.05),且治疗后观察组各项指标均明显优于对照组(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:早期应用纳洛酮治疗肺性脑病临床指标明显改善,不良反应发生率少,安全性高,值得在临床上推广使用。
Objective: To observe and analyze the efficacy and safety of naloxone in the treatment of patients with pulmonary encephalopathy. Methods: 50 patients with pulmonary eneephalopathy were randomly divided into the observation group and the con- trol group. All the patients were carried out continuous oxygen with non-invasive ventilator. The control group was treated with the con- ventional treatment, and the observation group was given naloxone on the basis of eonventinal treatment. The treatment course was 7 days. The clinical efficacy, clinical indicators and adverse events of the two groups were observed. Results: The total effective rate of the observation group reached 92.00%, which was higher than that of the control group without statistical significance (72.00%, P 〉 0.05). The levels of pH, PaO2, PaCO2, angiotensin Ⅱ and IL-8 were significantly improved in both groups after the treatment (P 〈 0.05 ), and the improvement in the observation group was much better than that in the control group (P 〈 0.05 ). The incidence of ad- verse reactions of the two groups after the treatment showed no significant difference ( P 〉 0.05 ). Conclusion: Early application of naloxone in the treatment of pulmonary encephalopathy can improve the clinical indices significantly with low incidence of adverse reac- tions and high safety, which is worthy of promoted use in clinics.
作者
韩正贵
彭万军
王文静
Hart Zhenggui Peng Wanjun Wang Wenjing(Department of Internal Medicine Department of Cardiology Department of Critical Care Medicine, Sanya Chinese Medicine Hospital, Hainan Sanya 572000, China)
出处
《中国药师》
CAS
2017年第2期293-295,共3页
China Pharmacist